#INFORM TARGET DRIVER#

Research Institute we have built a set of projects based on the use of iPSC derived neurons particularly in Alzheimer's and Parkinson's disease. In Neurodegeneration we are using the collective expertise of our partners and through collaboration with UCL and the Cambridge Dementia Immuno-oncology as well as intersections with the role of the immune system in neurodegenerative disease. We also have projects that intersect with oncology including identification of receptor ligand pairs in NK cells with application to Or in disease such as asthma using single cell genomics. T cells in response to various stimulations, Gene editing and single cell transcriptomics and epigenetic profiling (for instance in microglia, macrophages, dendritic cells and We are probing the roles of targets either in well-defined immune cells through Loci implicated from genetics for IBD and SLE. In addition, we are generating eQTL datasets including at the single cell level that can be used to resolve the causal genes at We developed a state of the art meta-analysis for theĮxisting IBD cohorts, and we are moving candidate targets into CRISPR-cas9 knockouts in gut epithelium organoids for validation. Is a strong interest from our partners and expertise on the Genome Campus. We focus on explaining the genetic basis of immune-mediated diseases including inflammatory bowel disease (IBD) and SLE where there Microenvironment or alter cell killing in co-culture. Identifying potential combination targets, and immuno-oncology targets by identifying targets that modify the tumour We are expanding our gene editing approaches to both tumour based cancer targets for instance by Lethality from genome editing in model systems that best reflect the biology of tumours can identify many new targetīehan et al 2019. Genomic information including RNA-seq and synthetic Lines at the Sanger Institute along with their drug sensitivities. A key resource is the unique collection of >1000 human cancer cell

#INFORM TARGET DRIVER#

Resources to curate and analyse clinical genomic datasets to identify driver genes (mutations, amplification, deletionsĪnd gene fusions) across multiple cancer sub-types. A shared theme is the use of accessible cancer Which has played an important role in understanding the genetic basis of cancer. Our projects in Oncology utilise resources and expertise within the Wellcome Sanger Institute'sĬancer, Ageing and Somatic Mutations Program,

We work together with scientistsĪcross our partner organisations to identify areas where our research programme will enhance target identificationĪnd prioritisation either by integrating and analysing data, or by generating new data in our therapeutic areas of Such as target tractability by drug modality, and likely target-based safety risks. Refines the list of targets on the strength of the association evidence and additional target and disease parameters Target identification defines targets with significant associations to the disease biology. We consider target selection to encompass two key steps, target identification and target prioritisation. We bring these approaches together in an integrated Types of data to be generated to inform target selection. In addition, feasibility of new technologies in gene editing, single cell sequencing and cell models allow new New data from modern genetics and genomics allows targets to be assessed in a comprehensive genome-wide context. At Open Targets, we are improving how targets are selected for drug discovery.ĭrugs against genetically validated targets are more likely to progress through clinical trials.

Inform target